The development of molecules able to modulate the vascular endothelial growth factor (VEGF)-dependent angiogenic response is crucial to treat diseases depending on excessive vascularization, such as rheumatoid arthritis and psoriasis, degenerative eye conditions and tumor growth and metastasis, or on insufficient angiogenesis, such as ulcers and ischemic heart disease. The gene discussed is VEGFA; the disease is neoplasm.